Home · XERF vs Thermage: the FDA Predicate
Close relatives, not rivals. XERF's FDA clearance rests on substantial equivalence to the Thermage FLX — a regulatory finding, not a clinical verdict. Here is what that does and does not tell you.
They are close relatives, not rivals. XERF received US FDA 510(k) clearance K251327 on 11 August 2025 specifically on the basis that it is substantially equivalent to the Thermage FLX. Both are non-invasive monopolar radiofrequency devices. The difference XERF introduces is a second operating frequency — 2 MHz alongside the 6.78 MHz that Thermage uses.
Device A
Device B
It is a regulatory finding, not a clinical one. Under the US 510(k) pathway a manufacturer demonstrates that a new device has the same intended use and comparable technological characteristics to a device already legally on the market — the predicate. It is a route to market. It is not a head-to-head trial, and it is not a statement that the two devices produce identical results in a patient.
So the honest reading is this: XERF's clearance tells you it belongs to the same family as Thermage and was assessed against it. It does not tell you that XERF is better. Anyone who presents an FDA predicate as proof of superiority has misunderstood the document, or is hoping you will.
Worth knowing, because it is not what most marketing implies. The K251327 indication for use reads: “XERF is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.” That is the cleared wording. Skin tightening is how monopolar radiofrequency devices are used and marketed in aesthetic practice, and that gap between cleared indication and clinical use is common across this whole device category — Thermage included. It is not a scandal. But you should hear it from the clinic rather than discover it later.
Thermage has the deeper literature, simply because it has been in use far longer. XERF's published evidence is small and new, and both papers we can point to are open access, so you can read them yourself rather than take our word for it.
The first is a letter to the editor in Skin Research and Technology reporting histological findings after dual-frequency treatment — thickened and shortened collagen bundles and thicker fibrous septa. Histology is real evidence of a tissue effect. A letter to the editor is not a controlled clinical trial, and it does not establish how a face looks at six months.
The second is a technical report in Cureus on periorbital tightening with newly engineered small applicators. Its authors are commendably careful: they describe improvements in eyebrow position and upper-eyelid redundancy at three months, then state plainly that these observations are anecdotal and are not presented as quantitative outcomes. We are repeating that caveat rather than quietly dropping it.
Where we stand. Elea Clinic offers XERF and does not offer Thermage, so treat this page as informed but interested. If you already have good results from Thermage elsewhere, there is no clinical reason to switch on the strength of a newer clearance date.
The contraindications are shared, because the underlying energy is the same. Monopolar radiofrequency is not appropriate if you have an implanted electronic device such as a pacemaker or defibrillator, or metal implants in the treatment field. It is not performed during pregnancy. Active infection or inflammation in the treatment area defers treatment. Isotretinoin use, keloid tendency and certain autoimmune conditions all need discussing before, not after.
For most patients the device matters less than three other things: whether a doctor has correctly diagnosed the kind of laxity you actually have, whether the operator is trained on the specific platform, and whether the energy settings are chosen for your skin rather than read off a protocol card. A well-run Thermage will beat a poorly-run XERF, and the reverse is equally true.
If you are still deciding between technology families rather than brands, the XERF versus HIFU comparison is the more useful page — those two are genuinely different, where XERF and Thermage are cousins.
Sources.
Hong J, Ryu HG, et al. Efficacy of dual-frequency noninvasive monopolar radiofrequency in skin tightening: histological evidence. Skin Research and Technology 2024;30:e13821. doi:10.1111/srt.13821
Erlich G, Dahan E, Skorochod R, Wolf Y. Dual-frequency non-invasive monopolar radiofrequency for periorbital tightening: introduction of novel small treatment tips. Cureus, published 9 January 2026. doi:10.7759/cureus.101187
US FDA 510(k) database, premarket notification K251327, decision date 11 August 2025, predicate K170758.
Ask before you book, not after.
Send a photograph and your concern. dr. Jesslyn will tell you what is appropriate — or whether a different treatment is.
Book a dermatologist consultation Replies Monday–Saturday 9.30am–7pm WITA, usually within 30 minutes.Is XERF the same as Thermage?
No, but they are closely related. Both are non-invasive monopolar radiofrequency devices. XERF received US FDA 510(k) clearance K251327 on the basis of substantial equivalence to the Thermage FLX, which is its legal predicate. XERF adds a second operating frequency of 2 MHz alongside the 6.78 MHz that Thermage uses.
Does an FDA predicate mean XERF is better than Thermage?
No. Substantial equivalence is a regulatory route to market showing the same intended use and comparable technological characteristics to a device already legally marketed. It is not a head-to-head clinical trial and establishes no superiority in either direction.
What is XERF actually cleared for?
The K251327 indication for use reads: “XERF is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.” Skin tightening is how monopolar radiofrequency devices are used in aesthetic practice, and the gap between cleared indication and clinical use is common across this device category, Thermage included.
How much published evidence is there for XERF?
Little, and it is recent. Two open-access papers are available: a 2024 letter to the editor in Skin Research and Technology reporting histological collagen changes, and a 2026 technical report in Cureus on periorbital tightening whose authors state that the outcome observations are anecdotal and not quantitative. Thermage has a substantially larger literature accumulated over roughly two decades.
Who cannot have monopolar radiofrequency?
Anyone with an implanted electronic device such as a pacemaker or defibrillator, or metal implants in the treatment field. It is not performed during pregnancy. Active infection or inflammation in the area defers treatment. Isotretinoin use, keloid tendency and some autoimmune conditions require assessment first.
Does Elea Clinic offer Thermage?
No. Elea Clinic offers XERF and was the first clinic in Bali to do so. This page is written by a clinic that offers one of the two devices, and should be read with that in mind.
Should I switch from Thermage to XERF?
Not on the strength of a newer clearance date. If Thermage is producing good results for you, a newer predicate device is not a clinical reason to change. Operator training and correct diagnosis of your pattern of laxity matter more than the brand on the handpiece.
Medically reviewed by dr. Jesslyn Amelia, Sp.D.V.E — Dokter Spesialis Dermatologi, Venereologi dan Estetika. Registered with the Indonesian Ministry of Health, STR JT00000382760637. Verify registration. Last reviewed 8 September 2026. Individual results vary; this page is general information and not a substitute for consultation.